Introduction
Thrombin is a pivotal player in the intricate scenario that ensurcs haemostasis when riggered by injury but that leads to thrombosis when set off inappropriately. Thombin generation is due to a complex enzymatic mechanism by which, in triggered plasma, thrombin is first formed and subsequently inactivated-In ivo, this process is closely intertwined with functions of blood cells and vessels. Nevertheless, aii circumstances that reduce the thrombin generating capacity of plasma (e.g. every form of anticoagulation) have an antithrombotic and haemonhagic effect, and all conditions that increase thrombin generation (e.g. deficiencies of antithrombin or the proteins C or S, APC resistance) foster tlnombosis (see also Fig. 1 ). Therefore the ttuombin generating capacity of plasma is one of the main determinans of haemoslasis and thrombosis. In the managementof anticoagulant therapy and for the detection of thrombosis and bleeding risks ' we need a laboratory parameter that expresses this function. Since more than a century clotting times are used for this purpose, but they are insensitive to hypercoagulation and barely sensitive to moderate coagulation defects. Moreover a plasma sample clots already when only 1G-20 nM of thrombin are formed, at a moment that the large majori ty (>95Vo) of thrombin has still to be generated. Consequently, feahres of the thrombin generating process that take place after clotting has occurred are notreflected in the clotting time. A classical example is the thromboplastin time, that is hardly prolonged even if the amount of thrombin formed is substantially decreased by the presence of heparin (see Fig. 2 ). There is a need for a parameter that decreases upon hypocoagulation of any kind and increases in hypercoagulability' in proportion to the amount of active thrombin that is fonned during coagulation in aplasma sample' The limiteddataavailable at this moment suggest that the ETP, contrary to the PT and the APT[, is a parameter that derreases upon hlpocoagulation of any kind and increases in hypercoagulability, in proportion to the thrombin forming capacity of a plasma sample (1'2).
The potency of thrombin generation of the plasma is not to be confused with the extent of ongoing thrombin generation in the body. Fragme nt 1.2 e.g. reflects that tkombin is being generated in the body. It is a smoke detector that reports an ongoing fire. A test for hypo-or hypercoagulability however should indicate the fire risk, i.e. the potential thrombin-forming capacity of the non triggered system. The difference between the nrro appears e.g. in DIC (disseminated inravascular coagulation) with consumption coagulopathy, where the indicators of ongoing coagulation are high but the capacity of the plasma to generate thrombin is low.
The mechanlsm of thrombln generatlon
In the mechanism of thrombin generation three essentially different types of action can be recognized, thatcan be represented by three axis: X) Thrombin production and inactivation in the sfrict sense of the word, Y) Modulation of the reaction velocity nd Z) Lncalization at the site of vascular damage. In Fig. l the X and Y axis are shown, the Z axis is not rendered. These processes cooperate at the level of single enzyme complexes; e.g. prothrombin conversion as such is carried out by factor Xa, with a velocity that is determined by the availability of factor Va and the process remains confined to the surface of a procoagulant membrane. The ordinate.Tlte core of the thrombin generation mechanism is the production inactivation axis. Thrombin is produced by the well known "cascade" mechanism, i.e. the tissue factor faclor VIIa complex (TF-VIIa) activates factor X, factor Xa activates prothrombin (3-5). The resulting thrombin is inactivated by antithrombin ( N) (47 Vo), ormacroglobulin (o.rl'/)(-147o) and minor inhibitors (-9Vo).Ttrc production is limited in time by the tissue factorpathway inhibitor (TFPI): When a sufficient amount of factor Xa is formed, the generation of more factor Xa is shut down because a XaTFPI complex forms that efficiently inhibits further activity of TFVIIa (6). Factor IX is activatedby the factor VIIaTF complex like factor X is. Together with factor VItra it forms an altemative factor X activator that is not inhibited by TFPI but the activity of which is modulated by factor VIII activation and inactivation (see below). This reinforcement loop (the Josso loop) probably constitutes an escape mechanism that, at low TF, prevents precocious arrest of factor Xa formation via the TFPI mechanism.
The abscissa. The second axis is modulation of thrombin generation velocity via activation and inactivation of factor V and factor VIII. In their activated form these factors enhance the proteolytic activity of their parhers (F.Xa and F.IXa resp.) approximately a thousand fold (3-5). The appearance and disappearance of factor Va (VIIIa) is governed by thrombin. Activation of factor V in plasma can be inhibited by hirudin, so factor Xa is not likely to be the physiological activator (l). The inactivation of factor Va (VtrIa) is also thrombin dependent because the scavenger of factor Va (VIIIa), activated protein C, is generated by the thrombomodulin thrombin complex (7, 8) .
Factor V is probably preferably activated by meizothrombin at a phospholipid surface (9) whereas factor VIII is kept in solution by von Willebrand factor and activated by thrombin in free solution. Meizothrombin is insensitive to the AT enhancing effectof heparin (10), whichmay explain why the thromboplastin time is relatively insensitive to heparin. Under the conditions of the APfi, however, the lag time of thrombin formation is mainly dependent upon the feedback activation of factor VIII by free thrombin, and therefore is sensitive to heparin.
The thi rd axi s. Several reactions in thrombin generation (indicated by boxes in Fig. 1 ) proceed to a significant extent only when the reactants arc adsorbed onto aphospholipid membrane that contains phosphatidylserine (PS). Such membranes occur at sites where endothelial integrity is lost,so thatthrombin generation isconfined tolesions in the vasculature. PS is almostexclusively foundat the cytoplasmatic side of cell membranesandis hardly exposedatthe exterior of the cell (11). When a vessel is damaged, cell damage will offer some PS containing membranes to the plasma. TF meets factor VII and so starts the coagulafion cascade. Moreover collagen is exposed to which can further cause platelet adhesion (12). As soon as traces of thrombin are formed, the simultaneous action of thrombin and collagen induces hansbilayer movement of PS in the platelet membrane and the platelet surface becomes procoagulant (l 1).
PS containing membranes enhance the velocity of ttrrombin generation because clotting factors meet more easily when adsorbed at these surfaces. Prothrombin, e.g., reaches the prothrombinase complex by diffusion in the plane of the surface (13). The apparcnt Km of prothrombin conversion, (i.e. the concentration of prothrombin in solution that is necessary to half saturate prothrombinase) decreases proportionally with the size of the procoagulant surface that is available around a prothrombinase molecule. Thrombin formation by a prothrombinase complex on a large procoagulant surface is so fastthat, underphysiologicalconditions, the velocity of itsaction is determined by the velocity at which prothrombin can be delivered to the surface rather than by the capacity of the enzyme (k*,= 3600 mini, Km= 5 nM, 13).
The thrombin generation mechanism is so replele with positive and negative feedback mechanisms that its kinetics show a strongly nonlinear behaviour. On the one hand parameters may vary without changing the output very much, on the other hand, small changes in one or more of the constituent activities may have unexpected, and unexpectedly large, effects on the output (14,6). Thisprecludes that anyof the isolated functions within the mechanism will adequately render the function of the whole. In order to assess the function of the thrombin generation mechanism one therefore has to measure thrombin, under conditions that are as near as possible to those in vivo.
The endogenous thrombln potentlal
We can imagine that in an areawhere thrombosis develops, the number of natural substrate molecules (fibrinogen, membrane receptors etc) that is cleaved by thrombin, determines the extent of the thrombotic response. If the thrombin substrale is not exhausted (which fibrinogen e.g. easily is) then the number of molecules converted by thrombin is proportional to both the concenbation of this enzyme and the time that itcan act, i.e. to the area under the thrombin time curve (Ftg.2).Therefore this area reflects the amountof (natural) subshate that couldpotentially be converted by ttre thrombin generated in the sample, also under in vivo conditions. We called it the endogenous thrombin potential (ETP) (2) . As such it is not new. The area under a thrombin generation curve has been used by Biggs and Macfarlane (15) to determine prothrombin, making the prothrombin concentration the only variable in the system. We, on the contary, use it to assess the combined effect of all the factors that may influence thrombin generation in a given sample.
Time (min) Fig. 2 . A thrombin generation curve obtained by subsampling. I : amidolytic activity on 52238; ! : ttuombin activity; + : oqM-IIa activity; x: amidolyiic activity in the presence of 0.05 U/ml of unfr actionated heparin.
After thrombin generation is over and free thrombin has disappeared we measure a residual amidolytic activity (Fig.2) . This is due to the c,, macroglobulin thrombin complex (crM-IIa). A simple mathematical procedure allows to split the experimental curve into the part due to free thrombin and the part that is due to this complex (Fig.2, see also below ).
How to measure the endogenous thrombln potentlal
The obvious way to determine the ETP is to calculate the area under the thrombin time curve such as it can be obtained by subsampling from aclotting plasma sample @g.2). This method is labourintensive and unsuitable for use in the clinical laboratory. Another approach is to simply add an artificial thrombin subshate (e.g. a chromogenic substrate) to the sample and determine the amount of product that is converted after the thrombin generation process is over. If the subshate is not exhausted, then the concentration of product will be proportional to the amount of any other @hysiological) subsrate that could potentially be converted by the thrombin generated in that plasma, i.e. to the ETP. There are some practical problems though. In the firstplace none of the conventional thrombin substrates can be used because any concentration that can be added will be consumed before thrombin generation is over. Thus we need a substrate that is cleaved slowly. Yet it has to be specific for thrombin, because, if it would bind significantly to another clotting enzyme, it would interfere with the thrombin generatiorr process. Preferably the subshate should be consumed to a limited exbnt (<lo7o),in order for the product formed to remain lineady proportional to the surface under the thrombin generation curve. We found two substrates that fulfil these conditions (Iable l). moment therefore is proportional (constant = k) with the time integral of free thrombin. So B(t) is the integral of A(t) multiplied by k. In practice the integral can be replaced by the sum of all values of A at that moment available. It follows that at measuring point n in time, the total amount of product formed @n) equals the amount converted by free thrombin (A") plus the arnount of product formed by k.(Ao+A,+......+A*,), so P, = A" + k (Ao+A,+.'....+A,-,). It follows that An equals (l -k).A*,+(P"-P*,). In this way the course of An can be calculated from the experimental data (i.e. the coune of P,) if k is known. This (sample dependent) constant can be found by trial and error, because, from the moment on that no free thrombin is left, 4 will not increase further. Itis easy to write aprogram inwhich atime seriesofP is entered and that calculates a time series of A with any assumed value of k. That value of k that renders a steady end level of A in the end phase of the reaction, when no more free thrombin is generated, is the right value. The steady end level of A then is proportional to the ttrombin potential by a factor F [=(Km+Syt".,.S], with S being the substrate concenhation andKm and \, the kinetic constants of the conversion of the subatrate by thrombin.
The thrombin dependentpartof the curve can also be obtained directly, after inactivation of c,r-M, either enzymatically or by reacting its internal S-cysteinyl-g-glutamyl thiolester. Hydroxylamine, at 100 mM,effectivelydestroys c,rmacroglobulin activity. As an additional benefit it renders the fibrin clot translucent, probably because it constitutes a substrate for factor XIIIa that competes with fibrin and hence prevents the light scattering thatresults from crosslinking. We still have to determine if, and to what extent, hydroxylamine interferes with the normal thrombin generation mechanism. Preliminary results lead us to suppose that by addition of hydroxylamine the o2M effect can be abolished, so that the experimental OD.trace takes the form of curve A in Fig. 3 and the ETP can be determined as a simple endpoint measuremenl We adapted the ETP assay in defibrinated plasma to a Cobas laboratory automaton, which enables us to carry out more than 50 determinations per hour. The ETP in platelet rich plasma is not readily automated. In such plasma defibrination is impossible withoutremoving the platelets and the addition of hydroxylamine may damage the platelet membrane. For the time being the ETP of a platelet rich sample has to be determined via a The fibrin that forms in clotting plasma interferes with direct spectroscopic observation. This imposes defibrination of the sample or the addition of substances that render the clot translucent (see below). Fig. 3 shows an O.D. trace obtained with one of the substrates added to clotting defibrinated plasma. After thrombin generation is over, product formation continues, due !o the c, macroglobulin thrombin complex (cqM-IIa). Via a similar mathematical procedure as used to obtain the thrombin curve in Fig.2 , the O.D.hace can be dissected into the part that is due to free thrombin and the part that is the result of the action of the ofi-Ila complex on the subshate (Fig. 3) .
The O-D. signal [P(t)] consists of two parts. One [A(t)] is generated by the actionof free thrombin on the addedsubstrate andtheother [B(t)] by qM-IIa action. crrlrtl-tra is formed with a velocity proportional to the concenhation of free thrombin. The amount of crrM-IIa present at any 136 NH 9.2 <10 thrombin generation curve obtained by subsampling.
The ETP of normal individuals equals 382 nM'min + 52 (S.D.,n=86) (As the ETP represents a surface on the concentration time plane, its dimensions are concentration multiplied by time' i.e. nM.min. The value may vary somewhat between labs, dependent upon the calibration factor used to convefi OD changes into concentrations of thrombin. In clinical practice itis convenient to express the ETP as a Vo of the normal value). The ETP is hardly dependent upon the concentration of thromboplastin used' We prefer to measure the ETP after triggering with dilute recombinant hornan tissue factor because we think this to be nearest to the physiological situation. Triggering the ETP via the contact aciivation mechanism is equally well possible Fig'4 Fie. 5. The influence of the level ofvitamin K dependent factors on the ilP:ih;i";il"Il, X and VII were independently varied between 0 and tW" ia the influence on the ETP was measured'1: protfrombin; n : factor X; +: factor VII. oay Fie. 6. The course of tluomboplastin-time, anri-factor Xa activity ;e th; ItTP in " p"ti"nt n""ted f6r ttuombosis' +: ETP; ! : anti-factor i" *titirv; -i firomboplastin-time. Heparin was,administered from admission to day 9. oral anticoagulatlon rrom <uly 4 on' in a lust group of animals (n= 8) the diet decreased the ETP by over 35Vo (n= 8) with comparison to a control group (C.Nieuwenhuys, J.W.M. Heemskerk, S.B6guin, unpublished)'
The limiteddata available, show that ETP is increased both in congenital and in acquired hypercoagulant states. It is increased Ay IZVI in women using oral contraceptives (21)' In 6 patients thatwere hospitalizedwittr anactive venous thrombosis, the ETP was 132 t t6 Vo of tnenormal value, as compared to 109 t 13 in was not systematically increased ( 16 t l4%o), yetintwo out of 7 patients ii was increasedby 33Vo and4}Vo (K' Faber, S'B6guin' preliminary results).
We found the ETP to be increased in antithrombin deficiency ' Fie. 4. The course of the ETP after subcutaneous injection of on'nactionatea and low molecular weightheparin. In l2 healthy_volunteers heparin iniected subcutaneously at t = 0. The mean and S'EM are grven of'ttr" *ti"uitv of the ETP comiared to the preinjection sample' --i';0OO-ru '"tftactionated treiarin; l: 40 mg enoxaparin; + : 75 mg enoxapann.
The ETP In hypo-and hypercoagulation Up to this moment there are a number of different observations that suggest the ETP to be a sensitive indicator of hyper-and hypocoagulability butvatidation studies are still tobe performed' ftri Bfp is more sensitive to the effect of both unfractionatedand low molecular weight heparin than the APTI' A dose (Frg. 5) (18). Half normal ETP values are observed at about the following clotting factor concentrations: hothrombin: 507o, FYII:2Vo;FX: 107o. It is interesting to note that, when switching from heparin therapy to oral anticoagulation, theETP, unlike PT' APTT and anti-factor Xa activity seems to render the level of tJrc mixed heatment (Fig. 6) (19) . To our surprise the ETP, when measured in whole blood, decreased under the influence of aspirin (20) . In an ongoing study, rats are being tested for the influence of a fish oil containing diet on the ETP. It was found that 0123455789t01t r37 HEMKER AND BEGUIN It can be seen fromref . 22 that in presence of thmmbomodulin the ETP of normal plasma decreases more than that of patients with a protein S or a protein C deficiency. It also has been observed that APC resiscance is readily detected by determining the effect of APC on ttre ETP (GAF Nicolaes, G Tans, J Rosing, unpublished results).
ur-M Q-3 mM) is present in excess over thrombin (< 0.3 mM) during the whole of the thrombin generation process. Therefore the amount of orM-IIa formed after coagulation is proportional to the ETP as long as the same plasma is studied. This can be used to estimate the influence on the ETP of modifying additions such as thrombomodulin (to search for protein C and S deficiency and APC resistance), APC (fer APC resistance) or to investigate the influence of in uitro addition of anticoagulants (2).
Summary
Thrombin generationis apivotal functionofplasmain haemostasis and thrombosis. Its mechanism is essentially the classical cascade, the velocity of which is governed by the availability of factors Va and VIIIa and that is confined to the surface of the procoagulant membranes which appear at the site of"injury.
There is no routine testthatqqntitatively renders the thrombin forming capacity of a plasma sample. Clotting times (PTprothrombin time, APTT-activated partial romboplastin time) do not reflect ths sysl all thrombin generation and are insensitive to hypercoagulative states. The endogenous thrombin potential @TP), i.e. the area under the thrombin'generation curve, better represents this function.
We developed a method to assess the ETP in the routine laboratory. The first results,suggest that it is a sensitive indicator for every form of anticoagulation. It is increased in hypercoagulable states thus far sfudied, both congenital and acquired and can be designed to indicate deficiencies in protein C and S and APC (activated protein C) resistance.
